Maze Therapeutics, which had its IPO earlier this year, is using insights from genetics to develop small molecules - its most advanced program is for a genetic kidney disease

CEO Jason Coloma walks us through the science that is taking place at the company's South San Francisco headquarters, and descrbies the development programs. The lead program for APOL1-Mediated Kidney Disease is in phase 2, and a second for PKU and Chronic Kidney Disease will have important healthy volunteer proof of concept data this quarter.